Theravance Biopharma Inc. (TBPH)
NASDAQ: TBPH
· Real-Time Price · USD
11.15
0.10 (0.90%)
At close: Jul 03, 2025, 1:04 PM
11.15
0.00%
After-hours: Jul 03, 2025, 04:22 PM EDT
0.90% (1D)
| Bid | 10.7 |
| Market Cap | 557.51M |
| Revenue (ttm) | 65.27M |
| Net Income (ttm) | -58.33M |
| EPS (ttm) | -1.18 |
| PE Ratio (ttm) | -9.45 |
| Forward PE | -23.51 |
| Analyst | Buy |
| Ask | 11.4 |
| Volume | 65,540 |
| Avg. Volume (20D) | 292,014 |
| Open | 11.08 |
| Previous Close | 11.05 |
| Day's Range | 11.00 - 11.25 |
| 52-Week Range | 7.44 - 11.82 |
| Beta | -0.08 |
About TBPH
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol TBPH
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for TBPH stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Theravance Biopharma Inc. is scheduled to release its earnings on Aug 4, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-9.29%
Theravance Biopharma shares are trading lower afte...
Unlock content with
Pro Subscription
7 months ago
+8.64%
Theravance Biopharma shares are trading higher after the company reported better-than-expected Q3 sales results.
1 month ago · seekingalpha.com
Theravance Biopharma, Inc. (TBPH) Q1 2025 Earnings Call TranscriptTheravance Biopharma, Inc. (NASDAQ:TBPH ) Q1 2025 Results Conference Call May 8, 2025 5:00 PM ET Company Participants Rick Winningham - Chief Executive Officer Rhonda Farnum - Chief Business Officer A...
